Datapharm names Rich Cooper as CEO to lead company on growth journey
Feb 27, 2023
Datapharm is delighted to announce the appointment of Rich Cooper as CEO. Rich joins Peter Facchino, CFO, who joined the company in January.
Datapharm is delighted to announce the appointment of Rich Cooper as Chief Executive Officer. Rich will be responsible for all operational aspects of the business including directing and managing the company’s growth strategy, ensuring the company executes its mission to improve the accessibility, effectiveness and excellence of healthcare product information.
Rich has over 25 years’ experience within the Pharmaceutical Industry and Healthcare, with previous leadership roles at AstraZeneca, Abbvie, Otsuka and IQVIA, as well as working at a senior level within an NHS trust. His industry knowledge and experience bring great value to the business as Datapharm continues to drive innovation with its SaaS offerings, supporting Pharmaceutical companies with invaluable data insights and streamlining their organisational processes around medicines information.
Speaking about his new role, Rich said: “Datapharm is the prominent service provider in the medicines information sector in the UK, having strong relationships with the vast majority of companies holding medicinal product licences. I am looking forward to building on the position and increasing the breadth and depth of the services we offer to our clients. We are in the position of being able to guide our customers on their digital journeys, increase engagement with HCPs and improve patient outcomes worldwide. I am delighted to have joined and look forward to working with the impressive team here at Datapharm.”
Neil Rotherham, Chairman of Datapharm, said “We are very pleased to have secured a candidate of Rich’s calibre to be CEO. The company embraces the responsibility of being the leading provider of medicines information in the UK, leading by example on the technical standards required to improve outcomes in healthcare. Rich’s appointment represents the beginning of the next stage of the Datapharm story and is a pivotal moment in the company's development. His leadership qualities and broad industry and NHS experience will be a real asset going forward.”
Rich joins Peter Facchino, Chief Financial Officer, who joined the company in January. Peter was previously CFO at the global supply chain risk management company, Achilles. He brings a wealth of experience garnered from working at the healthcare analytics and information provider, Elsevier, where he spent 8 years across the Science, Technology and Medical information business holding senior roles in Finance and Corporate Strategy.
Datapharm has continued to invest in talent, knowledge and technology to support its customers in their digital journeys. A key driver behind this has been nurturing a healthy culture of care, collaboration and courage to create positive changes.
Datapharm’s innovative role in the development of new industry standards in medicines information is facilitating stronger HCP and patient engagement for Pharma companies, and broader medicines information accessibility for all.
Datapharm would like to thank outgoing CEO, Simon Abrams, who has helped transform Datapharm into the healthcare SaaS provider it is today.
Datapharm provides accurate, up-to-date medicines information to patients and healthcare professionals throughout the UK while supporting Pharma with their digital processes. It runs emc (electronic medicines compendium), the UK’s most comprehensive, trusted and accessible source of information on medicines, listing more than 10,000 medicines and attracting a growing audience of over 84 million visitors per year.
It is a pharma-preferred partner, providing innovative software solutions to support the Life Sciences and wider Healthcare sectors, serving more than 350 Pharma customers in the UK.
Datapharm partners with a wide range of professional and voluntary health organisations to improve health literacy and decision making about medicines for patients, carers, healthcare professionals and the pharmaceutical industry.